Bone Abstracts

Introduction: Osteoporosis is the most common bone disease embrittling. Prevention and treatment strategies are well defined and are always updated. The therapeutic decision is based on the individual risk of fracture, effectiveness and therapeutic tolerance. However, side effects attributed to treatment may exist. Thus, the benefit and risks of prescription drugs is optimized by the choice of the right time and the right treatment.

The objective of the study: Evaluation of the safety and effectiveness of osteoporosis treatments referred in 70 patients followed for postmenopausal osteoporosis.

Materials and methods: Descriptive study conducted with 70 patients followed for postmenopausal osteoporosis. The inclusion criterion was any postmenopausal woman with osteoporosis densitometry objectified by the same apparatus of the dual energy X-ray bone densitometry (Hologic). Were excluded those with secondary osteoporosis, densitometry osteoporosis before menopause, and those with disturbance of calcium and phosphate, factors that may influence bone metabolism and BMD results.

Were identified clinical and laboratory data, supplemented by BMD values (BMD) at the beginning and the middle of the first therapeutic sequence.

The variables studied were the tolerance of different therapeutic protocols referred to bone and their effectiveness in terms of BMD gains between the beginning and the middle of the first therapeutic sequence. The analytical study of values was conducted using the statistical tests student.

Results: They were 70 patients. The average age was 63 years with a standard deviation of 9,19. The average weight was 69 kg (S.D.=8.94). 75.70% were postmenopausal before age 50 years, beyond the other cases. Nine had a history of fracture with minimal trauma and eight cases among a first degree relative. Eight cases reported the presence of a family osteoporosis. The mean bone mineral density (BMD) values at the entrance of the study were: lumbar spine (2.68±0.64), femoral neck (−1.94±0.78), total hip (−2.12±0.99), forearm (−2.48±2.03).

Blood calcium and phosphate and uriaire was normal (mean serum calcium was 93 mg/l, serum phosphorus in 37.66 mg/l, 24 h urinary calcium 125 mg/24 h, 25 (OH) Vitamin D to 25 ng/ml and PTH in 45 ng/ml (12.54). The majority of patients was under bisphosphonates (alendronic acid as 48.60, 24.30 and 4.30% risedronate as zoledronic acid). 17.10% were under strontium ranelate, 4.30 and 1.40% in the denosumab as Raloxifene. Four patients reported having previously received hormonal treatment of menopause. The median duration of treatment was 24 months (10.7 and 51 months). Regarding side effects with treatment, there were 33.33% in strontium ranelate and 5.88% by bisphosphonates. There was a densitometric gain at three sites significant at the lumbar spine (0.049) and the forearm (0.095).

Discussion and conclusion: The main objective of the current recommendations for the treatment of osteoporosis is to prevent the occurrence or recurrence of fractures. The therapeutic decision is based on the individual risk of fracture,efficacy and degree of therapeutic tolerance. Few studies have compared the different molecules together. Our study showed the effectiveness of different treatments referred to bone densitometry with dice gain the middle of the therapeutic sequence, during the postmenopausal osteoporosis. Few side effects attributed to treatment were highlighted.